Home   HELP  /   AYUDA  /   求助 : help-desk@bctrials.org  /   (415) 476-5777 Click to print page  Print

Browse Trials


In response to COVID-19, some breast cancer trials have temporarily stopped enrolling new patients. Use the contact information in our trial listings to call or email the research site for information about a trial's status.

Visit COVID-19 & Cancer Clinical Trials on Metastatic Trial Talk for regularly updated information about clinical trials during the coronavirus pandemic.


Currently viewing trials
(Last updated: July 07, 2020)

Zip Code:
 

Narrow my choices:

Radius (miles): All U.S.

20 All U.S.
Early stage    Advanced 
Treatment    Non-treatment 
Phase    I     II     III 
Display Only New Trials 
 
Close
Treatment

BRCA1/2

Chemotherapy

Hormone Therapy

Radiation Oncology

Surgery

Surgery: Reconstruction

Targeted Therapy: All

Targeted Therapy: Anti-HER2 Therapy

Targeted Therapy: CDK Inhibitors

Targeted Therapy: PARP Inhibitors

Targeted Therapy: Tumor Mutations

Targeted Therapy: Other Targeted Therapy

Vaccines and Immunotherapy

Other Treatment

Non-Treatment

Activities

Complementary and Alternative Medicine

Decision Support

Diagnosing Breast Cancer

Genetics/Family History

Having Children

Lymphedema

Managing Side Effects

No Travel Required

Predicting Response to Treatment

Preventing Breast Cancer

Preventing Recurrence

Screening

Support/Education

Surveys/Interviews/Registries

1

NEAREST SITE: 682 miles
Fred Hutch/University of Washington Cancer Consortium
Seattle,WA

VISITS: 1 visit every 3 weeks

PHASE: I

NCT ID: NCT04120246

Alpha-TEA and Trastuzumab for Metastatic HER2 Positive Breast Cancer

A Phase I Dose Escalation Trial of Alpha-Tocopheryloxyacetic Acid (α-TEA) in Patients With Treatment Refractory HER2+ Metastatic Breast Cancer Scientific Title

Purpose
To study the best dose and effects (good and bad) of giving alpha-TEA in combination with trastuzumab (Herceptin®).
Who is this for?
People with metastatic (stage IV) HER2 positive (HER2+) breast cancer who have already received trastuzumab (Herceptin®), pertuzumab (Perjeta®), and trastuzumab emtansine (TDM-1) for metastatic disease.    Full eligibility criteria
Contact research site
Close

Contact Research Sites

  • What's involved?
  • What's being studied?
  • How can I learn more?
  • <p class="seamTextPara"> You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Alpha-TEA, by mouth, daily (2 weeks on, 2 weeks off), ongoing</li> <li class="seamTextUnorderedListItem">Trastuzumab (Herceptin®), by IV, every 3 weeks, ongoing</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">You will also receive your doctor's choice of hormone therapy if your tumor is hormone positive</i></p>
  • <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Alpha-TEA is a drug derived from vitamin E.</li> <li class="seamTextUnorderedListItem">Alpha-TEA may stimulate the immune system to fight cancer cells.</li> <li class="seamTextUnorderedListItem">Trastuzumab (Herceptin®) is commonly used to treat people with metastatic HER2 positive breast cancer.</li></ul>
  • <ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT04120246' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.cancer.gov/publications/dictionaries/cancer-drug/def/alpha-tocopheryloxyacetic-acid' target='_blank'>NCI Drug Dictionary: Alpha-Tocopheryloxyacetic Acid (Alpha-TEA)</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.breastcancer.org/treatment/targeted_therapies/herceptin' target='_blank'>Breastcancer.org: Trastuzumab (Herceptin®)</a> </li></ul>
See more